Biogen Attacks Bass Group's AIA Review Bid For MS Drug

By Vin Gurrieri ( October 19, 2015, 7:43 PM EDT) -- Biogen told the Patent Trial and Appeal Board on Friday to reject a bid by an organization with ties to hedge fund manager Kyle Bass to again consider instituting an America Invents Act review of a patent covering multiple sclerosis drug Tecfidera, saying the organization can't point to any error in the board's initial refusal....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

PTAB Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Date Filed

Subscribers Only

Law Firms

Companies

Patents